Valneva (VALN) secured marketing authorization in the UK for its Ixchiq vaccine for chikungunya, a mosquito-borne viral disease.
The vaccine, manufactured at the company's leading production site in Livingston, Scotland, got the approval from the Medicines and Healthcare products Regulatory Agency,
The single-dose vaccine is for active immunization for the prevention of disease caused by the chikungunya virus in people 18 years of age and older, Valneva said Wednesday in a statement.
The vaccine is approved in the US, Europe and Canada in adults, and Valneva expects to get marketing approval in Brazil in Q1.
Valneva submitted label extension applications in the US, Europe and Canada to possibly extend the use of Ixchiq to adolescents aged 12 to 17 years and plans to submit a label extension application in the UK.
The company's shares rose 14% in recent Wednesday trading.
Price: 6.43, Change: +0.82, Percent Change: +14.69
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。